Literature DB >> 15580382

One-lung ventilation for video-assisted thoracoscopic interruption of patent ductus arteriosus.

Kagami Miyaji1, Koui Ka, Hirotsugu Okamoto, Tai-ichi Takasaki, Kuniyoshi Ohara, Hirokuni Yoshimura.   

Abstract

PURPOSE: Video-assisted endoscopic techniques have recently been employed in congenital heart surgery for patent ductus arteriosus (PDA) interruption. We report our preliminary experience of using a new technique of single-lung ventilation to perform video-assisted thoracoscopic PDA interruption (VATS-PDA) in small infants and children.
METHODS: Sixteen infants with a mean body weight of 6.5 +/- 2.4 kg (range 2.6-12.8 kg) underwent VATS-PDA under selective right-lung ventilation using a 2-F balloon catheter for arterial embolectomy.
RESULTS: We did not need to reposition the retractor or reinflate the atelectatic lung, as there was no transient hypoxia or hypercarbia. The mean procedure time was 81 +/- 27 min (range 45-145 min) and all patients, with the exception of one with a total anomalous pulmonary venous connection, were extubated in the operating room.
CONCLUSION: This technique using single-lung ventilation for infants and small children was safe and effective in providing pediatric thoracic access and exposure within confined and delicate anatomic spaces.

Entities:  

Mesh:

Year:  2004        PMID: 15580382     DOI: 10.1007/s00595-004-2872-8

Source DB:  PubMed          Journal:  Surg Today        ISSN: 0941-1291            Impact factor:   2.549


  2 in total

1.  PDA clipping by video-assisted thoracoscopic surgery.

Authors:  Koh Takeuchi
Journal:  J Thorac Dis       Date:  2019-09       Impact factor: 2.895

2.  Desflurane improves lung collapse more than propofol during one-lung ventilation and reduces operation time in lobectomy by video-assisted thoracic surgery: a randomized controlled trial.

Authors:  Ryosuke Kawanishi; Nami Kakuta; Yoko Sakai; Yuki Hari; Hideto Sasaki; Ryo Sekiguchi; Katsuya Tanaka
Journal:  BMC Anesthesiol       Date:  2022-04-29       Impact factor: 2.376

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.